Background Research:
Age-related macular degeneration (AMD) is a common eye condition among people age 50 and older. It is a leading cause of vision loss in developed countries. AMD occurs when the macula, the part of the eye needed for sharp, central vision, begins to deterioritate. This often results in a gradual loss of central vision over time.
Two types of AMD are recognized: dry AMD (atrophic) and wet AMD (exudative). Dry AMD makes up roughly 80–90% of cases and it progresses slowly than wet AMD which is more severe, but less common.
Despite regular research efforts into better understanding this disease, it remains incurable with its causes not fully understood. The new research conducted by University Hospital Bonn (UKB) and the University of Bonn provides renewed hope for early detection which can lead to improved treatment or prevention.
FAQs:
1. What is age-related macular degeneration (AMD)?
2. What are some symptoms associated with AMD?
3. How does the new research help in treating or managing AMD?
4. Who conducted this new research on effective treatment and early detection methodologies for AMD?
5. What has these findings shown for patients already suffering from AMD?
6.How could these findings change current treatments available for those diagnosed with ARM?
7.Does early detection increase chances to treat or manage under control ARM?
8.What other therapies could possibly be tested due to these finding?
9.How will this potential improve the ability to thwart off blindness derived from ARM?
10.Whom will benefit most from these forward strides in ARM study?
Originamitteilung:
Findings could enable new therapies and improved treatments: New research by the University Hospital Bonn (UKB) in cooperation with the University of Bonn has shown for the first time that certain early changes in patients with age-related macular degeneration (AMD) can lead to a measurable local loss of vision. This discovery could help to improve the treatment and monitoring of this eye disease in older patients, which otherwise slowly leads to central blindness, and to test new therapies.